Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexandra Kachaner, Raphaèle Seror, Fleur Cohen Aubart, Julien Henry, Thierry Lazure, et al.. Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature. JBMR Plus, 2024, 8 (5), pp.ziae043. ⟨10.1093/jbmrpl/ziae043⟩. ⟨hal-04626829⟩
-
Robin Zagala, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, et al.. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. Journal of the European Academy of Dermatology and Venereology, In press, ⟨10.1111/jdv.20155⟩. ⟨hal-04626767⟩
-
-
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
-
-
Mots clés
EGFR
Prevention
Anti-PD1
ALK
Systemic therapy
Androgen insensitivity
Chemoresistance
Locally advanced
Follow-up
Acute generalized exanthematous pustulosis
Dabrafenib
Adjuvant FOLFOX
Immunohistochemistry
Colorectal carcinoma
Antineoplastic agents
Abscopal effect
BRAF V600-mutation
Mesenchymal stromal cells
Immunotherapy
Anti-PD1 blockade
Prognosis
Body mass index
Biomarker
AML
Osimertinib
Colorectal cancer
Melanoma
Cancer bronchique non à petites cellules
BRAF
Immunomodulation
Non-small cell lung cancer
Molecular targeted therapies
Metastatic
Diagnosis
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Prognostic
BRAF V600E
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Histiocytosis
Cancer
Lung adenocarcinoma
Abscopal effect colorectal cancer intratumoral immunotherapy liver metastases radiofrequency
Children
Trametinib
Cemiplimab
Beta-catenin
Polyomavirus
Sonic Hedgehog
Biomarkers Colonic neoplasms Machine learning Prognosis Tumour infiltrating lymphocytes
Anti-CTLA-4
Surgical excision
Bisphosphonates
ALK rearrangement
2-chlorodeoxyadenosine
Antibody-drug conjugate
Circulating cell-free DNA
ADN tumoral circulant
Biliopancreatic diversion
Nivolumab
ACTH
Safety
Wnt
BRAFV600E
TNM classification
Abdominal pain
Metastatic cSCC
Anti-Tumor pharmacology
Advanced melanoma
AZD9291
Colon cancer
Adjuvant therapy
Plasma
Biomarkers
Radiotherapy
Adverse events
Advanced
Staging
Anti-PD-1 antibody
Radiofrequency ablation
Circulating tumor DNA
Langerhans cell histiocytosis
Gastric bypass
BRAFV600-mutant melanoma
Anti-PD-1
BRAFV600E mutation
Resistance
Cutaneous squamous cell carcinoma
Chemotherapy
Adjuvant
Merkel cell carcinoma
Immune checkpoint inhibitor
Crizotinib
Allelic imbalance
Targeted therapy
Assisted reproductive techniques
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Invasive cutaneous squamous cell carcinoma
Treatment
Survival
Bariatric surgery